Understanding and Assessing Occupational Performance for Individuals With Parkinson's Disease

Abstract Date Presented 04/200/21 OT has a valuable role in promoting quality of life for individuals with PD in all aspects of daily life. The Canadian Occupational Performance Measure (COPM) enables practitioners to address the holistic needs of clients, rather than exclusively focusing on predetermined areas of disability. This study has shown that the full breadth of clients' needs are vast and varied and exist beyond those included in standardized assessment tools because only one-third of the items identified by the COPM were included in the Movement Disorder Society—Unified Parkinson's Disease Rating Scale. Primary Author and Speaker: Abdullah Alsaeed Additional Authors and Speakers: Kristen A. Pickett Contributing Authors: Maria Widmer

Download Full-text

Instrumental Activities of Daily Living (IADLs) for Individuals With Parkinson’s Disease: Results From the Canadian Occupational Performance Measure (COPM) as Compared to a Standardized Rating Scale

American Journal of Occupational Therapy ◽

10.5014/ajot.2020.74s1-po6722 ◽

2020 ◽

Vol 74 (4_Supplement_1) ◽

pp. 7411500045p1

Author(s):

Heidi Wagner ◽

McKenzie Meyer ◽

Emily Noldin ◽

Maria Mertzenich ◽

Monica Daleccio ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Activities Of Daily Living ◽

Daily Living ◽

Rating Scale ◽

Performance Measure ◽

Occupational Performance ◽

Instrumental Activities ◽

Canadian Occupational Performance Measure

Download Full-text

Salivary caffeine in Parkinson’s disease

Scientific Reports ◽

10.1038/s41598-021-89168-6 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Giorgio Leodori ◽

Maria Ilenia De Bartolo ◽

Daniele Belvisi ◽

Alessia Ciogli ◽

Andrea Fabbrini ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Rating Scale ◽

De Novo ◽

Oral Intake ◽

Caffeine Intake ◽

Motor Complications ◽

Disease Rating ◽

Caffeine Metabolism ◽

Movement Disorder Society

AbstractWe aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson’s disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.

Download Full-text